{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:41:46Z","timestamp":1788964906955,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,2]]},"DOI":"10.7759\/cureus.100644","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T05:18:32Z","timestamp":1767417512000},"source":"Crossref","is-referenced-by-count":2,"title":["Temporal Patterns of Adverse Events Associated With Selective Serotonin Reuptake Inhibitors: A Global Pharmacovigilance Analysis of Early-Onset Versus Late-Onset Toxicity"],"prefix":"10.7759","author":[{"given":"Adrian Chin Yan","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Selective serotonin reuptake inhibitors","author":"Chu A","year":"2025","unstructured":"Chu A, Wadhwa R. Selective serotonin reuptake inhibitors. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2767","article-title":"Adverse effects of antidepressant medications and their management in children and adolescents","volume":"43","author":"Strawn JR","year":"2023","unstructured":"Strawn JR, Mills JA, Poweleit EA, Ramsey LB, Croarkin PE. Adverse effects of antidepressant medications and their management in children and adolescents. Pharmacotherapy. 2023, 43:675-90. 10.1002\/phar.2767","journal-title":"Pharmacotherapy"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v65n0712","article-title":"Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate","volume":"65","author":"Hu XH","year":"2004","unstructured":"Hu XH, Bull SA, Hunkeler EM, et al.. Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004, 65:959-65. 10.4088\/jcp.v65n0712","journal-title":"J Clin Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1A254","article-title":"Discontinuing or switching selective serotonin-reuptake inhibitors","volume":"36","author":"Bull SA","year":"2002","unstructured":"Bull SA, Hunkeler EM, Lee JY, et al.. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother. 2002, 36:578-84. 10.1345\/aph.1A254","journal-title":"Ann Pharmacother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00861-y","article-title":"Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO global database of individual case safety reports","volume":"42","author":"Wakao R","year":"2019","unstructured":"Wakao R, Taavola H, Sandberg L, et al.. Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO global database of individual case safety reports. Drug Saf. 2019, 42:1487-98. 10.1007\/s40264-019-00861-y","journal-title":"Drug Saf"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.04.024","article-title":"Global burden of antidepressant-associated seizures from 1967 to 2023: a comparative analysis of the international pharmacovigilance database","volume":"381","author":"Cho H","year":"2025","unstructured":"Cho H, Lee K, Wang SM, et al.. Global burden of antidepressant-associated seizures from 1967 to 2023: a comparative analysis of the international pharmacovigilance database. J Affect Disord. 2025, 381:215-23. 10.1016\/j.jad.2025.04.024","journal-title":"J Affect Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241231116","article-title":"Safety profile of selective serotonin reuptake inhibitors in real-world settings: a pharmacovigilance study based on the FDA Adverse Event Reporting System","volume":"58","author":"Zhao Y","year":"2024","unstructured":"Zhao Y, Zhang Y, Yang L, Zhang K, Li S. Safety profile of selective serotonin reuptake inhibitors in real-world settings: a pharmacovigilance study based on the FDA Adverse Event Reporting System. Ann Pharmacother. 2024, 58:1105-16. 10.1177\/10600280241231116","journal-title":"Ann Pharmacother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1644241","article-title":"Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system","volume":"16","author":"Yu Q","year":"2025","unstructured":"Yu Q, Yao J, Li E, et al.. Neurological adverse events associated with antidepressants: a comprehensive 22-year analysis of the FDA adverse event reporting system. Front Pharmacol. 2025, 16:1644241. 10.3389\/fphar.2025.1644241","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.70285","article-title":"Effects of selective serotonin reuptake inhibitor (SSRI) use on cardiometabolic health and risk in young healthy individuals: a preliminary matched pairs study","volume":"13","author":"Shostak ES","year":"2025","unstructured":"Shostak ES, Lang JM, Quinn WK, et al.. Effects of selective serotonin reuptake inhibitor (SSRI) use on cardiometabolic health and risk in young healthy individuals: a preliminary matched pairs study. Physiol Rep. 2025, 13:e70285. 10.14814\/phy2.70285","journal-title":"Physiol Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-022-01174-3","article-title":"Drug-induced sexual dysfunction: an analysis of reports to a national pharmacovigilance database","volume":"45","author":"Valeiro C","year":"2022","unstructured":"Valeiro C, Matos C, Scholl J, van Hunsel F. Drug-induced sexual dysfunction: an analysis of reports to a national pharmacovigilance database. Drug Saf. 2022, 45:639-50. 10.1007\/s40264-022-01174-3","journal-title":"Drug Saf"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1517546","article-title":"Overweight and glucose\/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system","volume":"15","author":"Cao J","year":"2024","unstructured":"Cao J, Chen Z, Wang Y, et al.. Overweight and glucose\/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system. Front Pharmacol. 2024, 15:1517546. 10.3389\/fphar.2024.1517546","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.sxmr.2017.07.002","article-title":"Post-SSRI sexual dysfunction: a literature review","volume":"6","author":"Bala A","year":"2018","unstructured":"Bala A, Nguyen HM, Hellstrom WJ. Post-SSRI sexual dysfunction: a literature review. Sex Med Rev. 2018, 6:29-34. 10.1016\/j.sxmr.2017.07.002","journal-title":"Sex Med Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3233\/JRS-210039","article-title":"Characterizing post-SSRI sexual dysfunction and its impact on quality of life through an international online survey","volume":"32","author":"Studt A","year":"2021","unstructured":"Studt A, Gannon M, Orzel J, Vaughan A, Pearlman AM. Characterizing post-SSRI sexual dysfunction and its impact on quality of life through an international online survey. Int J Risk Saf Med. 2021, 32:321-9. 10.3233\/JRS-210039","journal-title":"Int J Risk Saf Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12991-023-00447-0","article-title":"Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants","volume":"22","author":"Ben-Sheetrit J","year":"2023","unstructured":"Ben-Sheetrit J, Hermon Y, Birkenfeld S, Gutman Y, Csoka AB, Toren P. Estimating the risk of irreversible post-SSRI sexual dysfunction (PSSD) due to serotonergic antidepressants. Ann Gen Psychiatry. 2023, 22:15. 10.1186\/s12991-023-00447-0","journal-title":"Ann Gen Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.afos.2017.05.002","article-title":"Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms","volume":"3","author":"Wadhwa R","year":"2017","unstructured":"Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms. Osteoporos Sarcopenia. 2017, 3:75-81. 10.1016\/j.afos.2017.05.002","journal-title":"Osteoporos Sarcopenia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint13030038","article-title":"Selective serotonin reuptake inhibitors and adverse effects: a narrative review","volume":"13","author":"Edinoff AN","year":"2021","unstructured":"Edinoff AN, Akuly HA, Hanna TA, et al.. Selective serotonin reuptake inhibitors and adverse effects: a narrative review. Neurol Int. 2021, 13:387-401. 10.3390\/neurolint13030038","journal-title":"Neurol Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00377","article-title":"Importance of low- and moderate-grade adverse events in patients' treatment experience and treatment discontinuation: an analysis of the E1912 trial","volume":"42","author":"O'Connell NS","year":"2024","unstructured":"O'Connell NS, Zhao F, Lee JW, et al.. Importance of low- and moderate-grade adverse events in patients' treatment experience and treatment discontinuation: an analysis of the E1912 trial. J Clin Oncol. 2024, 42:266-72. 10.1200\/JCO.23.00377","journal-title":"J Clin Oncol"},{"key":"ref18","article-title":"Improving Healthcare Quality in Europe: Characteristics, Effectiveness and Implementation of Different Strategies","author":"Panteli D","year":"2019","unstructured":"Panteli D, Legido-Quigley H, Reichebner C, Ollenschl\u00e4ger G, Sch\u00e4fer C, Busse R. Improving Healthcare Quality in Europe: Characteristics, Effectiveness and Implementation of Different Strategies. European Observatory on Health Systems and Policies, Copenhagen, Denmark; 2019."},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.5152\/npa.2016.12373","article-title":"Metabolic effects of antidepressant treatment","volume":"54","author":"Olguner Eker \u00d6","year":"2017","unstructured":"Olguner Eker \u00d6, \u00d6zsoy S, Eker B, Do\u011fan H. Metabolic effects of antidepressant treatment. Noro Psikiyatr Ars. 2017, 54:49-56. 10.5152\/npa.2016.12373","journal-title":"Noro Psikiyatr Ars"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020266","article-title":"Using machine learning for pharmacovigilance: a systematic review","volume":"14","author":"Pilipiec P","year":"2022","unstructured":"Pilipiec P, Liwicki M, Bota A. Using machine learning for pharmacovigilance: a systematic review. Pharmaceutics. 2022, 14:10.3390\/pharmaceutics14020266","journal-title":"Pharmaceutics"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02998-6","article-title":"Pharmacogenomic scores in psychiatry: systematic review of current evidence","volume":"14","author":"Sharew NT","year":"2024","unstructured":"Sharew NT, Clark SR, Schubert KO, Amare AT. Pharmacogenomic scores in psychiatry: systematic review of current evidence. Transl Psychiatry. 2024, 14:322. 10.1038\/s41398-024-02998-6","journal-title":"Transl Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.30773\/pi.2022.0209","article-title":"Confounding by indication in studies of selective serotonin reuptake inhibitors","volume":"19","author":"Lee J","year":"2022","unstructured":"Lee J, Chang SM. Confounding by indication in studies of selective serotonin reuptake inhibitors. Psychiatry Investig. 2022, 19:873-83. 10.30773\/pi.2022.0209","journal-title":"Psychiatry Investig"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13871","article-title":"Using electronic health records for clinical pharmacology research: challenges and considerations","volume":"17","author":"Jafari E","year":"2024","unstructured":"Jafari E, Blackman MH, Karnes JH, et al.. Using electronic health records for clinical pharmacology research: challenges and considerations. Clin Transl Sci. 2024, 17:e13871. 10.1111\/cts.13871","journal-title":"Clin Transl Sci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2024.1428831","article-title":"Integrating electronic health records with other data sources for postmarket drug safety signal identification: a review","volume":"4","author":"Kim JV","year":"2024","unstructured":"Kim JV, Davis SE, Matheny ME, Smith JC. Integrating electronic health records with other data sources for postmarket drug safety signal identification: a review. Front Drug Saf Regul. 2024, 4:1428831. 10.3389\/fdsfr.2024.1428831","journal-title":"Front Drug Saf Regul"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449207-temporal-patterns-of-adverse-events-associated-with-selective-serotonin-reuptake-inhibitors-a-global-pharmacovigilance-analysis-of-early-onset-versus-late-onset-toxicity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T05:18:32Z","timestamp":1767417512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449207-temporal-patterns-of-adverse-events-associated-with-selective-serotonin-reuptake-inhibitors-a-global-pharmacovigilance-analysis-of-early-onset-versus-late-onset-toxicity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.100644","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}